Yasumasa Yamada

Abstract Neuroblastoma, the most common extracranial solid tumor in children, is often associated with high-risk features and poor outcomes. Despite intensive multimodal therapies, survival remains unsatisfactory, underscoring the need for new treatments. Checkpoint kinase 1 (CHK1) and checkpoint kinase 2 (CHK2) are key regulators of the DNA damage response (DDR) and cell cycle checkpoints. We investigated the antitumor effect of their combined inhibition in neuroblastoma.

Abstract Neuroblastoma is one of the most common childhood tumors. As tumor suppressor genes are frequently silenced via promoter hypermethylation in cancers, targeting DNA methylation has become a promising therapeutic approach. Despite the therapeutic potential of targeting DNA methylation in neuroblastoma, conventional inhibitors of DNA methyltransferases (DNMTs) reportedly exhibit inadequate therapeutic efficacy and intolerable toxicity.